Wynnchurch Capital Buys PGHC Holdings

Wynnchurch Capital buys PGHC Holdings.
   
PGHC Holdings is the parent company of New England restaurant groups Papa Gino's Pizzeria and D'Angelo Grilled Sandwiches. 
    
This tones up the chains' financial assets, enabling PGHC to remodel and refresh their 141 eateries in Massachusetts, New Hampshire, Rhode Island, and Connecticut.  More restaurants are planned throughout the region, and enriched online ordering capabilities will cover all locations. 
   
Corey Wendland of PGHC said: 'We are happy to have reached an agreement that will ensure a long and prosperous future for these iconic New England restaurants.  For some time, we have been pursuing a plan to strengthen our financial footing and secure capital for investment in our restaurants, while also addressing our significant debt load.  We are confident that the agreement with Wynnchurch achieves all those goals.  Wynnchurch's investment will enable us to renew our legacy as a community-focused restaurant company, bringing back menu favorites, serving great-tasting, fresh, high-quality food, and delivering an outstanding customer experience.' 
   
Kathy Cruz of Papa Gino's said: 'I'm thrilled that we have a partner committed to revitalizing the brands and positioning us for future growth.  Together, we will be working tirelessly on delivering outstanding hospitality, improving service times and producing the best pizza in New England.'
   
Jim Croteau of D'Angelo said: 'I've been with D'Angelo for twenty-seven years because of our focus on hospitality and relationships - guests have always been at the forefront of every decision made.  I'm excited about having an opportunity to reboot and focus the operations team on the core values that built this great New England neighborhood sandwich shop.'

Comments

Post a Comment

Popular posts from this blog

Pepsi Buys Rockstar

Pepsi buys Rockstar .     P epsiCo buys Rockstar Energy Beverages for $3.85 billion.     Founded in 2001, Rockstar is drinks designed for people leading an active lifestyle. Available in 20 flavors at convenience and grocery stores in 30 countries. Distributed by PepsiCo in North America since 2009. Supporting the Rockstar lifestyle across the globe through action sports, motorsports, and live music. Pepsi's energy portfolio also includes Kickstart , GameFuel, and Amp Energy.     The deal reflects the shift from reliance on sales of sugary, fizzy drinks toward options ranging from tea and coffee to still and sparkling water varieties, which appeal to health-conscious and younger consumers. Neither PepsiCo nor Coca-Cola owns a major brand in the energy drinks category, which is forecast to grow to more than $80 billion over the next five years and is now dominated by Red Bull.     2 00 countries and territories around the world enjoy ...
Read more

Compass Buys Marucci

Compass buys Marucci.     Compass Diversified Holdings buys Marucci Sports for $200 million.     Marucci Sports was founded in 2009 by Kurt Ainsworth, a retired pitcher for the San Francisco Giants and Baltimore Orioles, Joe Lawrence, a former second baseman for the Toronto Blue Jays, and Reed Dickens, a former White House Assistant Press Secretary under George W. Bush.     Marucci ’s first buy was Marucci Bat Company, launched out of a backyard shed in 2004. Ainsworth then led the buyout of an Amish-run Pennsylvania wood mill in 2008. This solidified Marucci's superior wood supply, and it still supplies all Marucci's wood today. In 2017 Marucci bought Victus , a baseball equipment maker known for its edgy designs and big attitude.     With vertically cohesive wood bat production, a global supplier group, and a client base of MVPs and World Series winners, Marucci and Victus are the top two bats among Big League players. T...
Read more

Gilead Buys Forty Seven

Gilead buys Forty Seven.     Gilead Sciences buys Forty Seven for $4.9 billion.     Forty Seven is a clinical-stage immuno-oncology firm developing therapies targeting cancer immune evasion pathways and specific cell targeting approaches based on tech licensed from Stanford. Forty Seven’s lead program, magrolimab , is a monoclonal antibody against the CD47 receptor, a ‘don’t eat me’ signal that cancer cells commandeer to avoid being ingested by macrophages. Evaluated ant ibodies are in many clinical studies of patients with myelodysplastic syndrome, acute myeloid leukemia, non-Hodgkin lymphoma, and solid tumors. These assets complement the cell therapy franchise Gilead added with its 2017 buy of Kite Pharma .     Beyond magrolimab , Forty Seven is fixing to advance two more compounds into clinical testing. Developing FSI-174, an anti-cKIT antibody, in combination with magrolimab creates a novel, all-antibody conditioning regimen to address ...
Read more